Docket No.: A0345.0012 (PATENT)

Examiner: Not Yet Assigned

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Hamed Aissaoui et al.

Application No.: Not Yet Assigned Confirmation No.: N/A

Filed: Concurrently Herewith Art Unit: N/A

For: OUINOXALINONE-3-ONE

DERIVATIVES AS OREXIN RECEPTOR

ANTAGONISTS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir

In accordance with 37 CFR 1.97, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

\boxtimes	This	IDS	is l	being	filed	before	the	First	Office	Action	١.
-------------	------	-----	------	-------	-------	--------	-----	-------	--------	--------	----

This IDS is being filed after the issuance of the First Office Action but before the issuance of a Final Office Action².

¹ The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

 $^{^2}$ The IDS $\it must$ include $\it either$ a certification under 37 C.F.R. §1.97(e) or the fee set forth in 37 C.F.R. §1.17(p).

Fee Required by 37 C.F.R. § 1.97(c)(2) or 1.97(d)(2):

cited in a communication from a foreign patent office in a counterpart application less than thirty days prior to the filing of this information disclosure statement.

³ The IDS *must* include *both* a certification under 37 C.F.R. §1.97(e) *and* the fee set forth in 37 C.F.R. §1.17(p).

cited; or

least the relevant portion(s)⁶ of the communication from a foreign patent office in a counterpart foreign application in which the information was

⁴ A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) – (c). This exception does not apply to information cited in an International Application.

³⁷ C.F.R. §1.98(a)(3)(ii) requires that an English language translation be provided when a translation of the document, or portion thereof, "is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c)."

⁶ The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an "X", "x", or "A" indication on a search report, MPEP 8609 III A(3).

Application No.: Not Yet Assigned Docket No.: A0345.0012

This information is contained in the specification of the present application.

In accordance with 37 C.F.R. 1.98(d), copies of the cited documents are not enclosed as they were provided in application Serial No. , filed , which the present application relies upon for an earlier effective filing date under 35 U.S.C. 120.

Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: October 27, 2005

Respectfully submitted,

Charles E. Miller
Registration No.: 27,576
DICKSTEIN SHAPIRO MORIN &
OSHINSKY LLP
1177 Avenue of the Americas, 41st Floor
New York, NY 10036-2714
(212) 835-1400